PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique

Launched by XIJING HOSPITAL · Mar 30, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring a new imaging technique called dual-nuclide PET/CT imaging. This method aims to improve the way we visualize and measure different conditions like prostate cancer, neuroendocrine tumors, gliomas (a type of brain tumor), and Parkinson's disease. Researchers want to find out how accurately this imaging can identify and quantify these conditions in patients. The study will include 35 volunteers, with specific groups of patients diagnosed with these conditions and a few normal volunteers.

To be eligible for the study, participants need to be between 18 and 75 years old and meet certain health criteria based on their specific condition. For example, prostate cancer patients should have confirmed cancer with suspected spread, while glioma patients must have a confirmed diagnosis or strong suspicion of the tumor. Participants will undergo imaging tests in a comfortable setting and will need to sign an informed consent form to show they understand the study. It’s important to know that some individuals, such as those with serious health issues or recent treatments, may not qualify to participate. The trial is not yet recruiting, but it aims to provide valuable insights into better imaging techniques for these serious health conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age: 18 \~75 years old (including boundary values); Gender: male or female; Normal volunteers: males weighing ≥50kg, females weighing ≥45kg, and body mass index \[BMI = weight (kg)/height 2 (m2)\] within the range of 19.0 \~ 26.0kg/m2 (including borderline values); patients with prostate cancer: patients with pathologically-confirmed biochemical relapsed or primary diagnosed prostate cancer with highly suspected systemic metastases on conventional imaging or PSA levels; patients with neuroendocrine tumour patients: patients with NET (G2-G3) or NEC confirmed by pathology and highly suspected of having more than 3 metastases by conventional imaging; patients with glioma: patients with glioma confirmed by pathology or highly suspected by enhanced MRI and proposed to undergo surgical resection; patients with Parkinson's syndrome: patients with high clinical suspicion of Parkinson's syndrome.
• • Subjects can fully understand and voluntarily participate in this experiment and sign an informed consent form.
• Exclusion Criteria:
• • Those who cannot tolerate intravenous drug delivery methods (e.g., history of needle and blood sickness); those with alcohol allergy; and those who, in the opinion of the investigator, are unsuitable to undergo or are unable to complete imaging studies such as PET for specific reasons; Under 18 years of age or ECOG score \> 2; Less than 1 month after completion of radiotherapy and less than 2 months after completion of octreotide treatment in patients with neuroendocrine tumours; Women during pregnancy and breastfeeding; Practitioners requiring prolonged exposure to radioactive conditions; Serious diseases of heart, kidney, lung, vascular, nervous and mental systems, immunodeficiency diseases and hepatitis/cirrhosis; Participation in other interventional clinical trials within 1 month prior to screening; Presence of other conditions that, in the opinion of the investigator, make participation in this study unsuitable.